| 2.395 -0.045 (-1.84%) | 04-24 13:43 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.11 |
1-year : | 3.67 |
| Resists | First : | 2.66 |
Second : | 3.14 |
| Pivot price | 2.4 |
|||
| Supports | First : | 1.89 |
Second : | 1.58 |
| MAs | MA(5) : | 2.36 |
MA(20) : | 2.33 |
| MA(100) : | 2.14 |
MA(250) : | 2.26 |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 35.9 |
D(3) : | 31.4 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 3.97 | Low : | 1.32 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LYEL ] has closed below upper band by 49.5%. Bollinger Bands are 30% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.55 - 2.57 | 2.57 - 2.58 |
| Low: | 2.33 - 2.34 | 2.34 - 2.36 |
| Close: | 2.42 - 2.44 | 2.44 - 2.46 |
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Thu, 18 Apr 2024
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4.6% - MarketBeat
Tue, 16 Apr 2024
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts (NASDAQ:LYEL) - Seeking Alpha
Tue, 16 Apr 2024
Great week for Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional investors after losing 5.5% over the previous year - Simply Wall St
Thu, 11 Apr 2024
Lyell Immunopharma (NASDAQ:LYEL) Trading Up 4.9% - MarketBeat
Wed, 13 Mar 2024
Can Lyell Immunopharma Inc (LYEL) Stock Rise to the Top of Healthcare Sector Wednesday? - InvestorsObserver
Tue, 12 Mar 2024
LYEL Stock Quote Price and Forecast - CNN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 254 (M) |
| Held by Insiders | 1.6335e+008 (%) |
| Held by Institutions | 15.5 (%) |
| Shares Short | 10,950 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.2525e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -454 % |
| Return on Assets (ttm) | 392.3 % |
| Return on Equity (ttm) | -18.2 % |
| Qtrly Rev. Growth | 130000 % |
| Gross Profit (p.s.) | 0.33 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -0.76 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -164 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0.3 |
| Price to Book value | 0 |
| Price to Sales | 12.45 |
| Price to Cash Flow | -0.53 |
| Dividend | 0 |
| Forward Dividend | 1.81e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|